Balonkibart Biosimilar Monoclonal Antibody (NPR-A) for Research

Cat No.: GMP-Bios-INN-1094

Anti-NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA therapeutic antibody (Pre-made Balonkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Balonkibart (development code REGN-7544) is a human monoclonal antibody targeting natriuretic peptide receptor 1 (NPR1). It is developed by Regeneron Pharmaceuticals for sepsis-induced hypotension and postural orthostatic tachycardia syndrome. It has completed Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1094-1mg 1mg 3090
GMP-Bios-INN-1094-10mg 10mg
GMP-Bios-INN-1094-100mg 100mg
GMP-Bios-INN-1094-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Balonkibart biosimilar, Whole mAb, Anti-NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA Antibody: Anti-NPR1/Atrial natriuretic peptide receptor 1/Atrial natriuretic peptide receptor type A (ANP-A/ANPR-A therapeutic antibody
INN Name Balonkibart
Target NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC